CN109725160A - 一种降钙素原(pct)检测试剂盒 - Google Patents
一种降钙素原(pct)检测试剂盒 Download PDFInfo
- Publication number
- CN109725160A CN109725160A CN201811653771.5A CN201811653771A CN109725160A CN 109725160 A CN109725160 A CN 109725160A CN 201811653771 A CN201811653771 A CN 201811653771A CN 109725160 A CN109725160 A CN 109725160A
- Authority
- CN
- China
- Prior art keywords
- reagent
- pct
- procalcitonin
- latex
- centrifuged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010048233 Procalcitonin Proteins 0.000 title claims abstract description 89
- CWCXERYKLSEGEZ-KDKHKZEGSA-N procalcitonin Chemical compound C([C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC(=O)[C@H]1NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](N)CSSC1)[C@@H](C)O)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 CWCXERYKLSEGEZ-KDKHKZEGSA-N 0.000 title claims abstract description 89
- 238000001514 detection method Methods 0.000 title claims abstract description 37
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 89
- 229920000126 latex Polymers 0.000 claims abstract description 48
- 239000004816 latex Substances 0.000 claims abstract description 43
- 239000002245 particle Substances 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 18
- 239000000872 buffer Substances 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 15
- 101000741445 Homo sapiens Calcitonin Proteins 0.000 claims abstract description 7
- 229940045644 human calcitonin Drugs 0.000 claims abstract description 7
- 239000003755 preservative agent Substances 0.000 claims abstract description 4
- 230000002335 preservative effect Effects 0.000 claims abstract description 4
- 239000004005 microsphere Substances 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 239000006228 supernatant Substances 0.000 claims description 8
- 238000002604 ultrasonography Methods 0.000 claims description 8
- 238000005119 centrifugation Methods 0.000 claims description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 6
- 239000007995 HEPES buffer Substances 0.000 claims description 6
- -1 N- morpholinyl Chemical group 0.000 claims description 6
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 claims description 5
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 5
- 239000007853 buffer solution Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 230000010355 oscillation Effects 0.000 claims description 4
- 230000004913 activation Effects 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 claims 1
- YAVVGPBYBUYPSR-UHFFFAOYSA-N benzene;oxygen Chemical group [O].C1=CC=CC=C1 YAVVGPBYBUYPSR-UHFFFAOYSA-N 0.000 claims 1
- 235000019441 ethanol Nutrition 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 abstract description 13
- YFHIKONGZDBOMY-UHFFFAOYSA-N propane-1-sulfonate;propylazanium Chemical compound CCC[NH3+].CCCS([O-])(=O)=O YFHIKONGZDBOMY-UHFFFAOYSA-N 0.000 abstract description 9
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 abstract description 8
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract description 7
- 239000011248 coating agent Substances 0.000 abstract description 5
- 238000000576 coating method Methods 0.000 abstract description 5
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract 2
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 abstract 1
- 235000011164 potassium chloride Nutrition 0.000 abstract 1
- 239000001103 potassium chloride Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 27
- 230000000052 comparative effect Effects 0.000 description 23
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 11
- 238000003908 quality control method Methods 0.000 description 11
- 239000003795 chemical substances by application Substances 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 8
- 238000004879 turbidimetry Methods 0.000 description 7
- 239000003381 stabilizer Substances 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical group OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 2
- 102000055006 Calcitonin Human genes 0.000 description 2
- 108060001064 Calcitonin Proteins 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 239000001116 FEMA 4028 Substances 0.000 description 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 229960004853 betadex Drugs 0.000 description 2
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 2
- 229960004015 calcitonin Drugs 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 229960005323 phenoxyethanol Drugs 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 206010070545 Bacterial translocation Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000007375 bacterial translocation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- WSVDSBZMYJJMSB-UHFFFAOYSA-N octadecylbenzene Chemical compound CCCCCCCCCCCCCCCCCCC1=CC=CC=C1 WSVDSBZMYJJMSB-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811653771.5A CN109725160B (zh) | 2018-12-30 | 2018-12-30 | 一种降钙素原(pct)检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811653771.5A CN109725160B (zh) | 2018-12-30 | 2018-12-30 | 一种降钙素原(pct)检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109725160A true CN109725160A (zh) | 2019-05-07 |
CN109725160B CN109725160B (zh) | 2021-03-23 |
Family
ID=66298623
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811653771.5A Active CN109725160B (zh) | 2018-12-30 | 2018-12-30 | 一种降钙素原(pct)检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109725160B (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110514826A (zh) * | 2019-08-30 | 2019-11-29 | 山东博科生物产业有限公司 | 一种稳定、灵敏的抗环瓜氨酸肽抗体检测试剂盒 |
CN111337691A (zh) * | 2020-03-20 | 2020-06-26 | 中拓生物有限公司 | 一种灵敏、稳定的血清降钙素原测定试剂盒及其制备方法和应用 |
CN112798794A (zh) * | 2020-12-30 | 2021-05-14 | 迪亚莱博(张家港)生物科技有限公司 | 一种α1酸性糖蛋白检测试剂盒 |
CN113125741A (zh) * | 2019-12-30 | 2021-07-16 | 深圳市帝迈生物技术有限公司 | 降钙素原的检测试剂、试剂盒、系统及检测方法 |
WO2021151820A1 (de) * | 2020-01-28 | 2021-08-05 | Diasys Diagnostic Systems Gmbh | Diagnostisches reagenz zur quantitativen bestimmung von procalcitonin in einer probe |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102759631A (zh) * | 2012-08-02 | 2012-10-31 | 南京诺尔曼生物技术有限公司 | 一种定量检测降钙素原pct的胶乳增强免疫比浊试剂盒 |
CN103823070A (zh) * | 2014-03-21 | 2014-05-28 | 北京强申医学科技有限公司 | 一种高灵敏度的胱抑素c测定试剂盒 |
CN103940986A (zh) * | 2014-03-24 | 2014-07-23 | 安徽省煦棠医疗科技有限公司 | 肌钙蛋白i 特定位点抗体制备及其检测试剂盒 |
CN104133063A (zh) * | 2014-06-09 | 2014-11-05 | 浙江省海洋水产研究所 | 一种河豚毒素检测试剂盒 |
CN105842458A (zh) * | 2016-03-24 | 2016-08-10 | 山东盛百灵医药科技有限公司 | 一种降钙素原测定试剂盒及其降钙素原的含量的测定方法 |
CN106018816A (zh) * | 2016-05-27 | 2016-10-12 | 安徽伊普诺康生物技术股份有限公司 | 一种测定降钙素原的试剂盒 |
CN106568944A (zh) * | 2016-10-03 | 2017-04-19 | 王贤俊 | 一种检测AGEs的胶乳免疫比浊试剂盒 |
CN108872606A (zh) * | 2018-08-14 | 2018-11-23 | 山东博科生物产业有限公司 | 一种高度稳定、灵敏的结合珠蛋白(hp)检测试剂盒 |
-
2018
- 2018-12-30 CN CN201811653771.5A patent/CN109725160B/zh active Active
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102759631A (zh) * | 2012-08-02 | 2012-10-31 | 南京诺尔曼生物技术有限公司 | 一种定量检测降钙素原pct的胶乳增强免疫比浊试剂盒 |
CN103823070A (zh) * | 2014-03-21 | 2014-05-28 | 北京强申医学科技有限公司 | 一种高灵敏度的胱抑素c测定试剂盒 |
CN103940986A (zh) * | 2014-03-24 | 2014-07-23 | 安徽省煦棠医疗科技有限公司 | 肌钙蛋白i 特定位点抗体制备及其检测试剂盒 |
CN104133063A (zh) * | 2014-06-09 | 2014-11-05 | 浙江省海洋水产研究所 | 一种河豚毒素检测试剂盒 |
CN105842458A (zh) * | 2016-03-24 | 2016-08-10 | 山东盛百灵医药科技有限公司 | 一种降钙素原测定试剂盒及其降钙素原的含量的测定方法 |
CN106018816A (zh) * | 2016-05-27 | 2016-10-12 | 安徽伊普诺康生物技术股份有限公司 | 一种测定降钙素原的试剂盒 |
CN106568944A (zh) * | 2016-10-03 | 2017-04-19 | 王贤俊 | 一种检测AGEs的胶乳免疫比浊试剂盒 |
CN108872606A (zh) * | 2018-08-14 | 2018-11-23 | 山东博科生物产业有限公司 | 一种高度稳定、灵敏的结合珠蛋白(hp)检测试剂盒 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110514826A (zh) * | 2019-08-30 | 2019-11-29 | 山东博科生物产业有限公司 | 一种稳定、灵敏的抗环瓜氨酸肽抗体检测试剂盒 |
CN113125741A (zh) * | 2019-12-30 | 2021-07-16 | 深圳市帝迈生物技术有限公司 | 降钙素原的检测试剂、试剂盒、系统及检测方法 |
WO2021151820A1 (de) * | 2020-01-28 | 2021-08-05 | Diasys Diagnostic Systems Gmbh | Diagnostisches reagenz zur quantitativen bestimmung von procalcitonin in einer probe |
CN111337691A (zh) * | 2020-03-20 | 2020-06-26 | 中拓生物有限公司 | 一种灵敏、稳定的血清降钙素原测定试剂盒及其制备方法和应用 |
CN112798794A (zh) * | 2020-12-30 | 2021-05-14 | 迪亚莱博(张家港)生物科技有限公司 | 一种α1酸性糖蛋白检测试剂盒 |
CN112798794B (zh) * | 2020-12-30 | 2023-11-17 | 迪亚莱博(张家港)生物科技有限公司 | 一种α1酸性糖蛋白检测试剂盒 |
Also Published As
Publication number | Publication date |
---|---|
CN109725160B (zh) | 2021-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109725160A (zh) | 一种降钙素原(pct)检测试剂盒 | |
WO2018129885A1 (zh) | 一种全血c反应蛋白检测试剂盒 | |
CN111337691B (zh) | 一种灵敏、稳定的血清降钙素原测定试剂盒及其制备方法和应用 | |
CN103558400A (zh) | 一种降钙素原乳胶增强免疫比浊法检测试剂盒 | |
CN104198723A (zh) | 一种基于氨基酸间臂的ngal快速检测试剂盒 | |
CN110007074B (zh) | 用于检测c反应蛋白的试剂盒、其制备方法及用途 | |
CN108956982B (zh) | 一种类风湿性关节炎标志物联合定量检测试纸及其制备方法 | |
CN101893619B (zh) | 改进乳胶悬浊液稳定性的方法 | |
CN101377506A (zh) | 磷脂酰肌醇蛋白聚糖-3化学发光免疫分析测定试剂盒及其制备方法 | |
CN110514826A (zh) | 一种稳定、灵敏的抗环瓜氨酸肽抗体检测试剂盒 | |
CN109613257A (zh) | 一种转铁蛋白(trf)检测试剂盒 | |
CN104407156B (zh) | 检测多糖结合蛋白(lbp)的胶乳增强免疫比浊试剂盒及其制备方法 | |
CN103454193A (zh) | 检测脂蛋白(a)的免疫比浊试剂盒及其制备方法 | |
CN105203771A (zh) | 一种血清淀粉样蛋白a测定试剂盒及其使用方法 | |
CN106370862B (zh) | 一种稳定、灵敏的纤维结合蛋白检测试剂 | |
CN113614539A (zh) | 一种粘液病毒抗性蛋白1的定量试剂盒 | |
CN111896748A (zh) | 一种抗链球菌溶血素o测定试剂盒 | |
CN108872606A (zh) | 一种高度稳定、灵敏的结合珠蛋白(hp)检测试剂盒 | |
CN106093416A (zh) | 一种一步法检测降钙素原的试剂盒及其制备方法 | |
CN104459105B (zh) | 一种检测lp的胶乳增强免疫比浊试剂盒及其制备方法 | |
CN108490187A (zh) | 一种稳定、灵敏的四型胶原蛋白(iv-c)检测试剂 | |
CN111912990B (zh) | 中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒 | |
CN108872607A (zh) | 一种α2-巨球蛋白(α2-MG)检测试剂盒 | |
CN111239404B (zh) | 一种可以同时检测尿样本和血清样本中的视黄醇结合蛋白的检测试剂盒 | |
CN105974121B (zh) | 一种含鱼明胶的生物制品稳定剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A test kit for Calcitonin (PCT) Effective date of registration: 20230628 Granted publication date: 20210323 Pledgee: Bank of Communications Ltd. Shandong branch Pledgor: BIOBASE BIODUSTRY (SHANDONG) Co.,Ltd. Registration number: Y2023980045843 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20210323 Pledgee: Bank of Communications Ltd. Shandong branch Pledgor: BIOBASE BIODUSTRY (SHANDONG) Co.,Ltd. Registration number: Y2023980045843 |